Abstract:Abstract High Grade Serous Ovarian Cancer (HGSOC) is a fatal disease that is typically detected at an advanced stage when there are limited modalities for effective treatment. Treatment efficacy against cancer is dependent on tumor metabolism and its adaptation for most therapies. Warburg effect is an important adaptation found in tumors where cells primarily catabolize glucose even in presence of sufficient oxygen and nutrients. Nevertheless, recent evidence suggests cells in tumor microenvironments remain dependent on mitochondrial ATP production via oxidative phosphorylation (OXPHOS). OXPHOS also represents a major metabolic pathway in cancer stem cells and tumor cells of relapse patients. Molecular signatures of glycolysis and OXPHOS are both detected in tumors. This points to the OXPHOS pathway as a potential therapeutic target in cancer. Here we apply a data mining approach to identify OXPHOS inhibitors to evaluate as candidates for therapies against HGSOC. High-Throughput Screening (HTS) on mechanistic targets like OXPHOS are cost prohibitive for academic laboratories. As an alternative, we deployed a data mining pipeline to find active chemical classes among 8415 available OXPHOS-related bioassays in the PubChem data repository. Active compound clusters frequently contain α,β-unsaturated carbonyl groups, which are also observed in both endogenous quinone electron carriers and atovaquone–a potent inhibitor of OXPHOS. Out of 312041 unique compounds tested in the assays, we selected 6 representative molecules from each of the 6 largest active chemical clusters to test for OXPHOS inhibition, ROS production, and reduced cancer cell proliferation. We assayed cell viability (MTT) to check for proliferation of human (OVCAR3, OVCAR5, OVISE) and mouse (ID8) ovarian cancer cells against 6 compounds, Oryzalin, Allylyestrenol, Esbiothrin, Lacidipine, Coumatetralyl, and CID929419 (MLS000713029), 72 h post treatment. ID8 and OVCAR5 significantly decreased cell proliferation after Lacidipine and Oryzalin treatment. Significant increase in intracellular ROS, a frequent consequence of OXPHOS inhibition, was observed in all cell lines after Lacidipine treatment. Elevated ROS was also observed in ID8 and OVISE cells after Esbiothrin treatment. To confirm OXPHOS inhibition as the mechanism of action, we performed Mito Stress Test on the Seahorse Analyzer and measured Oxygen Consumption Rate. Treatment with Oryzalin, Allylyestrenol, Esbiothrin, and Lacidipine significantly decreased basal respiration rate and ATP production in ID8 and OVCAR3 cells. This suggests that 4 of the 6 compound classes prioritized by the data mining pipeline inhibits OXPHOS in ovarian cancer cells. Thus, our pipeline provides an efficient alternative to HTS for identifying OXPHOS inhibitors. Next, we plan to test the in-vivo efficacy of these drugs against ovarian tumors in a mouse model and investigate their molecular mechanisms. Citation Format: Sejal T. Sharma, Liping Feng, Nicha Boonpattrawong, Lisa M. Barroilhet, Manish Patankar, Spencer S. Ericksen. Data mining of PubChem bioassay data reveals OXPHOS inhibitors with anti-cancer activity. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5341.

Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin

Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review

Ocoxin as a complement to first line treatments in cancer

Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer

Osmundacetone modulates mitochondrial metabolism in non-small cell lung cancer cells by hijacking the glutamine/glutamate/α-KG metabolic axis

Cyclovirobuxine D Inhibits the Growth of Osteosarcoma Cells Through the Induction of Autophagy Flux Arrest by Promoting Lysosomal Acidification

Synthesis, Assessment of Antineoplastic Activity, and Molecular Docking of Novel 2-Thioxo-oxazolidin-4-one Derivatives

Biochemical and Cellular Characterization of New Radio-Resistant Cell Lines Reveals a Role of Natural Flavonoids to Bypass Senescence

OSW-1: A Novel Anticancer Agent with Potent Anticancer Activity and Unique Mechanism of Action.

Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data

Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells

Enhancing Therapeutic Response and Overcoming Resistance to Checkpoint Inhibitors in Ovarian Cancer through Cell Cycle Regulation

Abstract 5341: Data mining of PubChem bioassay data reveals OXPHOS inhibitors with anti-cancer activity

Cellular and molecular mechanisms of oroxylin A in cancer therapy: Recent advances

Elucidating the Anticancer Mechanisms of Cinnamoyl Sulfonamide Hydroxamate: Insights From DNA Content Analysis and Gene Expression Profiling in Squamous Cell Carcinoma

In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer

Abstract 514: Salt-inducible kinase inhibitor OMX-0407 drives cell-cycle arrest in vitro and in vivo: An in-depth MoA analysis by phospho-proteomics

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer

Abstract C016: Oxidative Phosphorylation is a Metabolic Vulnerability in Chemotherapy Resistant Triple Negative Breast Cancer

Combination of oxaliplatin and β-carotene suppresses colorectal cancer by regulating cell cycle, apoptosis, and cancer stemness in vitro

A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities